Allogeneic CD4+ T Cell Infusion for Reversing T Cell Exhaustion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods, such as immunologic checkpoint inhibitors, are limited by T cell exhaustion, where tumor-specific T cells become impaired, and existing allogeneic cell therapies face risks of sustained engraftment and graft-versus-host disease.
Innovation Solution
Infusion of allogeneic lymphocytes depleted of CD8+ T cells, specifically expanding CD4+ T cells vaccinated against tumor or viral antigens, to break tolerance and reverse exhaustion of endogenous CD8+ T cells, reducing the risk of engraftment and GVHD while enhancing anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If allogeneic cell therapy is used to treat cancer, then anti-tumor immunity is enhanced, but the risk of sustained engraftment and graft-versus-host disease increases
Solution Approach 1:
The patent extracts and removes CD8+ T cells from the allogeneic lymphocyte population, retaining only CD4+ T cells. This selective extraction eliminates the harmful engraftment and GVHD-causing cells while preserving the beneficial CD4+ T cell-mediated anti-tumor immunity. The method specifically depletes CD8+ T cells through immunomagnetic separation or other selective removal techniques before administering the cell therapy to patients.
2Reliability
If immunologic checkpoint inhibitors are used to treat cancer, then T cell activity is enhanced, but T cell exhaustion limits the effectiveness
Solution Approach 1:
The patent applies preliminary action by administering lympho-depleting chemotherapy before the allogeneic CD4+ T cell infusion. This pre-treatment creates a permissive immunological environment that removes suppressive cells and enhances the ability of transferred CD4+ T cells to reactivate and sustain endogenous tumor-specific CD8+ T cells, thereby overcoming exhaustion before the main therapeutic effect is initiated.
3Reliability
If allogeneic lymphocytes are infused to reverse T cell exhaustion, then tumor regression is achieved, but sustained donor cell engraftment may occur
Solution Approach 1:
The patent removes CD8+ T cells which are responsible for sustained engraftment and GVHD, while preserving CD4+ T cells that provide transient help for tumor regression. The short-term presence of CD4+ T cells is sufficient to reactivate host immune responses without the long-term persistence problems associated with CD8+ T cell engraftment.
Data Source
AI summary
The invention provides methods and compositions for administration of allogeneic lymphocytes as an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells.